Enovis Co. (NYSE:ENOV) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC increased its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 110.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 224,224 shares of the company's stock after purchasing an additional 117,540 shares during the quarter. Jane Street Group LLC owned 0.39% of Enovis worth $9,839,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Enovis by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock worth $240,731,000 after buying an additional 75,348 shares during the last quarter. DAVENPORT & Co LLC increased its holdings in Enovis by 6.0% during the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after acquiring an additional 157,216 shares in the last quarter. Royce & Associates LP lifted its holdings in shares of Enovis by 2.8% in the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock valued at $108,409,000 after purchasing an additional 66,891 shares in the last quarter. River Road Asset Management LLC grew its position in shares of Enovis by 3.8% in the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock valued at $54,339,000 after purchasing an additional 45,762 shares during the last quarter. Finally, Boston Partners increased its stake in shares of Enovis by 27.1% during the 4th quarter. Boston Partners now owns 1,048,532 shares of the company's stock worth $46,034,000 after purchasing an additional 223,816 shares in the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 target price on shares of Enovis in a research note on Wednesday, April 9th.

Enovis Price Performance

Enovis stock opened at $34.17 on Thursday. The stock has a market capitalization of $1.95 billion, a P/E ratio of -15.60 and a beta of 1.79. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $53.84. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm's 50-day moving average is $35.46 and its two-hundred day moving average is $41.70.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. The firm had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Equities analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.